Skip to main
MYGN

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 80%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics is facing challenges, particularly in prenatal volume and Hereditary Cancer growth due to payer friction and lower revenue per test. The company lowered its guidance by $90M, indicating potential difficulties in reaching its full-year forecast. Despite strong HCT and GeneSight volumes and a refreshed sales force, the company's revenue declined and margins compressed by 460 bps year-over-year, leading to little potential for stock upside even if it meets its revenue guidance.

Bears say

Myriad Genetics is facing multiple challenges, including ongoing volume challenges and weakness in its Prenatal Health segment, which suggests that it may be losing market share or facing reduced relevance. The company's guidance has been lowered for the next few years, and its current business model may not be able to achieve profitability without divestiture of assets. While recent initiatives such as a focus on new products and an expanded sales force may help drive growth, risks to the entire medical and life science tools sector, including reduction in budgets and regulatory hurdles, may hinder the company's ability to achieve sustainable profitability. However, there is potential for upside if the company experiences a strong market adoption of existing products or a successful launch of new products.

Myriad Genetics (MYGN) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 80% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 5 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Sep 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.